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ABSTRACT
Human dendritic cells (DC) comprise 2 subsets—plasmacytoid CD123 and myeloid CD11c DC—that may
have distinct roles in the regulation of immunity after allogeneic hematopoietic stem cell transplantation. In
this study, we analyzed the kinetics of CD123 DC and CD11c DC reconstitution in 31 patients who
underwent transplantation with allogeneic granulocyte colony-stimulating factor–mobilized peripheral blood
(PB) stem cells from HLA-identical sibling donors after myeloablative conditioning. Lineage marker–negative
HLA-DR CD11c CD11c DC and lineage marker–negative HLA-DR CD123 CD123 DC, as well as
monocytes and lymphoid subsets, were enumerated in donor grafts and in the PB of patients at various time
points after transplantation. Reconstitution of both CD11c DC and CD123 DC to normal levels occurred
within 6 to 12 months and was not affected by the diagnosis, preparatory regimen, or graft composition.
However, PB CD11c DC and CD123 DC counts were significantly reduced in patients with acute GVHD
grade II to IV (at 1 and 3 months) and grade I (at 1 month). Patients with chronic GVHD instead showed
reduced CD123 DC counts only 6 months after transplantation. Moreover, treatment with steroids (>0.1
mg/kg) was significantly associated with reduced PB CD11c DC and CD123 DC counts at all time points
after transplantation. In multivariate analysis, only acute GVHD affected DC reconstitution early after
transplantation. These results will prompt new studies addressing whether DC reconstitution correlates with
immunity against infectious agents or with graft-versus-tumor reactions after PB stem cell allotransplantation.
© 2004 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Dendritic cells (DC) are potent antigen-present-
ng cells (APC) that play an essential role in the ini-
iation or regulation of immune responses [1]. In hu-
ans, 2 distinct subpopulations of circulating DC
ave been characterized within cells negative for lin-
age markers (lin) and positive for HLA class II
olecules [2-6]. CD11c DC (DC1) selectively ex-
ress CD13, CD33, and CD45RO, as well as the
06ranulocyte macrophage colony-stimulating factor re-
eptor, and are therefore thought to originate from
yeloid progenitors; CD123 (interleukin-3 receptor
chain) DC (plasmacytoid DC; DC2) lack myeloid
arkers and, because of the selective expression of
ymphoid-speciﬁc gene products (such as pre-T,
-like and Spi-B) [7,8], have been suggested to origi-
ate from lymphoid progenitors [9]. CD11c DC
roduce high levels of interleukin-12 and are potent
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DC Reconstitution in PBSC Transplantation
Bctivators of T-helper 1 (Th1) differentiation, whereas
D123 DC produce high levels of interferon-/
ut are poor stimulators of T-cell proliferation
2,6,10-13]. Moreover, various stimuli, such as inﬂam-
atory cytokines TNF- (tumor necrosis factor-), T
ell-derived molecules (CD40L), lipopolysaccharide,
nd other bacterial products—or viruses and their
roducts—can drive CD123 DC to differentiate in
itro into potent APC that may be capable of selec-
ively inducing Th2 (hence the name DC2) or T-
egulatory type 1 cells, but also Th1 differentiation,
epending on the experimental system [10-11,13-17].
t is therefore thought that CD11cDC and CD123
C might play distinct roles in alloimmune responses
hat occur in hematopoietic stem cell transplantation
HSCT) [18].
In recent years, several studies in murine models
f allogeneic HSCT have suggested that DC may play
role both in initiating graft-versus-host disease
GVHD) and in promoting immune reconstitution
fter transplantation [19-21]. In humans, it has been
roposed that graft CD123 DC may regulate
VHD after both bone marrow and peripheral blood
tem cell (PBSC) transplantation [11,22]. Although it
s conceivable that the reconstitution of the DC com-
artment after transplantation may be important for
mmune responses against both alloantigens and
athogens, very few data are available concerning the
inetics of myeloid and CD123 DC repopulation in
eripheral blood (PB) after allogeneic transplantation.
oreover, conﬂicting data have been published re-
arding the relationship between various transplanta-
ion-related factors—including the type of prepara-
ory regimen, GVHD prophylaxis, and GVHD—and
he reconstitution of CD11c DC and CD123 DC
n PB after transplantation [23-27]. In this study, we
how a correlation between the recovery of CD11c
yeloid DC and CD123 plasmacytoid DC after my-
loablative PBSC allogeneic transplantation and the
evelopment of acute GVHD (aGVHD), as well as
ith treatment with corticosteroids (CS).
ATERIALS AND METHODS
atients
Thirty-one adult patients who underwent an allo-
eneic PBSC transplantation from an HLA-matched
elated donor at the Institute “Seragnoli,” University
f Bologna, between June 1999 and October 2001
ere consecutively enrolled in this study after written,
nformed consent was obtained. Patients’ characteris-
ics are shown in Table 1. All patients had aliquots of
ach PBSC harvest collected and processed for anal-
sis of leukocyte subpopulations, as described below.
n addition, patients’ PB was drawn before and 1, 3, 6,
nd 12 months after transplantation to evaluate the
mmune reconstitution. a
B&MTStandard myeloablative regimens for conditioning
ere used, depending on the disease, as previously
eported [28]. In particular, total body irradiation
TBI; 800 cGy single dose) was performed in multiple
yeloma patients, who also received melphalan 120
g/m2 and cyclophosphamide 120 mg/kg. Busulfan
6 mg/kg and cyclophosphamide 200 mg/kg was used
n all 7 acute leukemia and 1 of 2 myelodysplasia
atients, whereas in 7 of 7 chronic myeloid leukemia
atients and 1 myelodysplasia patient, antithymocyte
lobulin (ATG) was added to the standard busulfan/
yclophosphamide conditioning regimen. Five of 5
atients with either non-Hodgkin lymphoma (n  4)
r Hodgkin disease (n  1) received busulfan 16
g/kg, cyclophosphamide 120 mg/kg, and ATG in
he conditioning regimen.
GVHD prophylaxis included cyclosporine and
hort methotrexate (days 1, 3, 6, and 11) in all
atients. Acyclovir 10 mg/kg intravenously every 8
ours was given from day 5 to day 25 and then
rally for 9 months. Preemptive treatment of cyto-
egalovirus disease was performed with intravenous
r oral ganciclovir in case of cytomegalovirus-positive
ntigenemia, which was tested weekly until day 120
able 1. Patient and Graft Characteristics
Variable Data
edian age, y (range) 42 (29-56)
iagnosis
Acute myeloid leukemia 6 (19%)
Acute lymphoid leukemia 1 (3%)
Myelodysplasia 2 (6%)
Chronic myeloid leukemia 7 (23%)
Multiple myeloma 10 (32%)
Non-Hodgkin lymphoma 4 (13%)
Hodgkin disease 1 (3%)
onditioning regimen
Bu-Cy 8 (26%)
Bu-Cy-ATG 8 (26%)
Cy-Mel-TBI 10 (32%)
Bu-Mel-ATG 5 (16%)
VHD prophylaxis: CyA MTX 31 (100%)
edian follow up, d (range) 392 (48-695)
raft composition, median (range)*
Total nucleated cells 1300 (592-2115)
Myeloid DC 2.1 (0.7-3.9)
Plasmacytoid DC 2.7 (1.1-6)
Monocytes 244 (86-577)
B cells 49 (18-158)
NK cells 48 (11-133)
T cells 259 (116-632)
CD4 T cells 139 (72-408)
CD8 T cells 107 (32-240)
CD34 cells 5.8 (3.3-26.2)
u indicates busulfan; Cy, cyclophosphamide; ATG, antithymocyte
globulin; Mel, melphalan; TBI, total body irradiation; CyA,
cyclosporin A; MTX, methotrexate; DC, dendritic cells.
Values are expressed as 106 cells per kilogram of recipient’s body
weight.fter transplantation. Acute GVHD was graded ac-
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1ording to Przepiorka et al. [29], whereas chronic
VHD (cGVHD) was classiﬁed according to the cri-
eria described by Shulman et al. [30].
onors
All donors were HLA-identical siblings. PBSC
ere mobilized with human recombinant granulocyte
olony-stimulating factor (Lenograstin; Aventis, Mi-
an, Italy), subcutaneously, twice daily, at 10 g/kg/d.
eukaphereses were started on day 5 and repeated
aily until the target CD34 cell dose (4  106 cells
er kilogram of recipient’s body weight) was reached.
fter written informed consent was obtained from the
onors, aliquots of each apheresis product were pro-
essed for analysis of leukocyte subpopulations, as
escribed below.
low Cytometry
Flow cytometry analysis of leukocyte subsets was
erformed on fresh samples of PB and apheresis prod-
cts. The following monoclonal antibodies were used:
uorescein isothiocyanate (FITC)–conjugated anti-
in (a mixture of anti-CD3, -CD14, -CD16, -CD19,
CD20, and -CD56), anti-CD34 (clone 8G12), anti-
D19 (clone 4G7), and anti-CD4 (clone SK3); phy-
oerythrin (PE)–conjugated anti-CD11c (clone
-HCL-3), anti-CD123 (clone 9F5), anti-CD56
clone My31), and anti-CD8 (clone SK1); Leukogate
a mixture of FITC-conjugated anti-CD45 and PE-
onjugated anti-CD14); peridin chlorophyll protein
PerCP)–conjugated anti–HLA-DR (clone L243);
nd PerCP-carbocyanin 5–conjugated anti-CD3
clone SK7), all from Becton Dickinson (Mountain
iew, CA). Appropriate isotype controls included
ITC-, PE- and PerCP-conjugated immunoglobulin
Ig)G1 and PerCP-conjugated IgG2a (Becton Dick-
nson), as well as FITC- and PE-conjugated IgG2b
Pharmingen, San Diego, CA). CD11c DC were
dentiﬁed as lin CD34 CD11c HLA-DR, and
D123 DC were identiﬁed as lin CD34 CD123
nd HLA-DR, as previously described [11,31].
onocytes, B cells, natural killer (NK) cells, and
D4 and CD8 T cells were identiﬁed, respectively,
s CD45 CD14, CD19, CD56, CD3 CD4,
nd CD3 CD8. For staining, aliquots of whole
lood or apheresis products containing up to 106 leu-
ocytes were incubated with the appropriate amount
f each monoclonal antibody for 15 minutes at room
emperature. Red blood cell lysis was performed by
sing FACS Lysing Buffer (Becton Dickinson) ac-
ording to the manufacturer’s instructions. Stained
ells were washed twice in phosphate-buffered saline,
nd then sample acquisition was performed within 2
ours on a FACSCalibur (Becton Dickinson). Analysis
as performed by using Cell Quest (Becton Dickin-
on) software. Absolute numbers of leukocyte sub- a
08opulations in each sample were deﬁned by multiply-
ng the percentage of each cell subset, as determined
y electronic gating during analysis, by the total white
lood cell count, as determined by automated cell
ounting (Coulter Gen-S; Coulter Immunotech, Mar-
eille, FR).
tatistical Analysis
Differences between groups were analyzed for
heir signiﬁcance by using the Student t test, analysis
f variance test, general linear model, nonparametric
ruskal-Wallis test, or 	2 test, as indicated. In partic-
lar, the 	2 test was used for categorical variables; for
ontinuous variables, normality was tested by the Kol-
ogorov-Smirnov test. If the assumption of normality
as not met, logarithmic transformation was applied.
hen the assumption of normality was met, differ-
nces between groups were tested by the Student t test
r analysis of variance. Variables that showed nonnor-
al distribution were tested by using nonparametric
nalysis (Kruskal-Wallis test). Multivariate analysis
as performed by the general linear model. Variables
ith a P value of at least .05 in univariate analysis were
ncluded. All statistical analyses were performed with
PSS software (SPSS Inc., Chicago, IL).
ESULTS
inetics of CD11c DC and CD123 DC
econstitution in PB after Transplantation of
llogeneic PBSC
Thirty-one patients, whose characteristics are
isted in Table 1 and who received an allogeneic gran-
locyte colony-stimulating factor–mobilized PBSC al-
otransplant, were enrolled in this study. After a me-
ian follow up of 392 days (range, 48-695 days), 23
atients (72%) were alive and in complete remission.
umbers of CD11c DC, CD123 DC, and mono-
ytes were measured in the PB of all patients at 1, 3, 6,
nd 12 months after transplantation and in the PB of
7 healthy donors, as normal controls. CD11c DC
nd CD123 DC counts in the PB of control donors
ere (mean 
 SD) 18.7 
 11.2  106/L and 11.6 

 106/L, respectively, as shown in Figure 1 (shaded
rea). As shown in Figure 1 (top), CD123 DC were
ery few or undetectable in the blood of most patients
month after transplantation, but their median count
ncreased over the observation period up to 1 year
fter transplantation. Similarly, the median PB
D11c DC count also increased until 1 year after
ransplantation, as shown in Figure 1 (center). How-
ver, monocyte counts were already within the normal
ange as early as 1 month after transplantation (Figure
, bottom). These results suggest that a profound
eduction of DC, but not monocytes, occurs after
llogeneic PBSC transplants conditioned with my-
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DC Reconstitution in PBSC Transplantation
Bloablative regimens and that the full reconstitution of
ormal levels of CD11c DC and CD123 DC may
ake as long as 6 months to 1 year after transplanta-
ion.
We then tested whether DC recovery correlated
ith patient-related factors (such as age or disease) or
ransplant-related factors (such as the type of prepa-
atory regimen or the composition of the graft; Table
). It is interesting to note that younger patients (age
41 years) had signiﬁcantly greater median numbers
f both circulating CD11cDC (11.7 106/L; range,
.3-30.5) and CD123 DC (4.2  106/L; range, 0.2-
3.3) than the older ones (2.9 106/L; range, 0.3-17.9
nd 0.6  106/L; range, 2.3-30.5, respectively, for
D11c DC and CD123 DC; P  .01 and .05,
espectively) at 1 month after transplantation, but the
ifference was no longer observed at 3 through 12
igure 1. Kinetics of DC reconstitution in recipients’ PB after
llogeneic PBSC transplantation. CD123 DC (top), CD11c DC
middle), and monocytes (bottom) circulating in the PB at 1 month
n  31), 3 months (n  27), 6 months (n  20), and 12 months
n  15) after transplantation were enumerated by ﬂow cytometry,
s described in Materials and Methods. Each circle represents an
ndividual patient. The horizontal bars represent median values,
hich are also expressed as numbers on top of each dot plot. The
haded gray areas indicate the mean 
 SD PB levels of CD123
C, CD11c DC, and monocytes in 27 age-matched healthy con-
rol donors.onths. Furthermore, patients’ disease and the pres- l
B&MTnce of either ATG or TBI in the preparatory regi-
en did not affect DC recovery. Moreover, the re-
overy of CD11c DC or CD123 DC was not
ifferent in patients who received a higher dose of
raft CD11c DC (2.1  106/kg) or CD123 DC
2.7  106/kg; Table 2).
mpaired DC Reconstitution in Patients Who
eveloped aGVHD
To test whether DC reconstitution was affected by
GVHD, patients were divided according to the grade
f GVHD: 10 patients (32%) did not develop any
igns or symptoms of aGVHD, 13 patients (42%)
eveloped aGVHD grade I, and 8 patients (26%)
eveloped grade II to IV aGVHD. The 3 groups were
hen compared for PB CD11cDC and CD123DC
econstitution at 1 and 3 months after transplantation.
s shown in Figure 2 (top), patients with aGVHD
rade I or II-IV had signiﬁcantly lower PB CD123
C median counts than patients with no GVHD at 1
onth after transplantation (P  .037 and .027, re-
pectively). At 3 months after transplantation, PB
D123 DC counts were similar in patients with no
VHD or aGVHD grade I, whereas they were still
igniﬁcantly lower in patients with aGVHD grade II
o IV (P  .03). Acute GVHD had already developed
t the time of the ﬁrst ﬂow cytometric analysis (ie, 30
ays after transplantation) in 20 of 22 patients,
hereas 2 patients developed GVHD after 39 and 45
ays, respectively. It is interesting to note that in both
hese patients, the occurrence of aGVHD was fol-
owed by a profound reduction in PB CD123 DC
ounts at 3 months after transplantation (13.3  106
nd 0.2  106, and 7.9  106 and 0.2  106 CD123
C per liter, respectively, at 1 and 3 months). Median
D11c DC counts were also reduced in patients
ith aGVHD grade I at 1 month after transplantation
nd in patients with aGVHD grade II to IV at 1 and
months after transplantation as compared with pa-
ients with no GVHD, but the differences were not
tatistically signiﬁcant (Figure 2, center). The number
f monocytes was similar in all 3 groups at each time
oint (Figure 2, bottom). Moreover, we did not detect
ny difference in PB B cell, NK cell, and CD8 T-cell
ounts among the 3 groups, either at 1 or at 3 months
fter transplantation, whereas PB CD4 T-cell counts
ere signiﬁcantly reduced in patients with aGVHD
rade II to IV at 3 months after transplantation (not
hown).
To test whether DC reconstitution was also sim-
larly affected by cGVHD, PB CD11c DC and
D123 DC counts were analyzed in patients with
GVHD (n  12; 10 extensive and 2 limited) and in
hose without cGVHD (n  9). Twenty-one patients
ere evaluable, with a median follow up of 485 days
range, 131-695 days). Patients with cGVHD had
ower PB CD123 DC counts at 6 months (P  .04),
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1ut not at 1 year, after transplantation (Figure 3, top),
hereas no difference was observed in PB CD11c
C and monocytes (Figure 3) or in B-, T-, and NK-
ell counts (not shown). To rule out the possibility
hat reduced PB CD123 DC counts in patients with
GVHD could depend on the earlier occurrence of
GVHD in those patients, PB CD123 DC counts at
months after transplantation were compared among
GVHD groups. Patients with previous aGVHD (n
1; 9 grade I and 2 grade II to IV) had a median PB
D123 DC count of 5.4  106/L (range, 2.2-10.4 
06/L) at 6 months after transplantation, and this was
omparable to counts of patients who previously had
ot experienced any aGVHD (n  7; 5.5  106/L;
ange, 2.4-7.3  106/L), thus excluding a delayed
ffect of aGVHD on PB CD123 DC reconstitution.
ollectively, these data suggest that the development
f aGVHD or cGVHD may selectively correlate with
slower CD123 DC and, possibly, CD11c DC
econstitution for up to 6 months after allogeneic
BSC transplantation.
ffect of Steroids on DC Reconstitution
Because CS represent a ﬁrst-line therapy for
VHD and may be responsible for many GVHD-
elated immunosuppressive effects, we hypothesized
hat they could play a role in the observed reduction of
D123 DC and CD11c DC blood levels in pa-
ients with GVHD. To test whether treatment with
teroids for at least 3 to 5 days correlated with the
umbers of DC in PB, all collected samples, irrespec-
ive of the time of collection, were divided depending
n the dose of steroids that the patient was taking at
he time of the blood draw. As shown in Figure 4,
atients treated with prednisone doses 0.1 mg/kg
ad signiﬁcantly lower numbers of both CD11c DC

able 2. Correlation Between Pretransplantation Characteristics and D
Variable
Myeloid
1 mo 3 mo
ge .01* .38
isease
Multiple myeloma .53 .52
Acute leukemia .29 .28
hronic myeloid leukemia .17 .1
reparatory regimen
ATG containing .63 .2
TBI containing .68 1
raft composition
Plasmacytoid DC >2.7  106 ND ND
Myeloid DC >2.1  106 .83 .08
umbers of myeloid DC and plasmacytoid DC circulating in recipie
compared according to the presence or absence of the indicated
as described in Materials and Methods, is expressed as P value.
TG indicates antithymocyte globulin; TBI, total body irradiation
values 0.05 were considered signiﬁcant.nd CD123 DC. The effect seemed to be dose re- *
10igure 2. Acute GVHD correlates with reduced PB CD123 DC
nd CD11c DC numbers at 1 and 3 months after transplantation.
B numbers of CD123 DC (top), CD11c DC (middle), and
onocytes (bottom) were compared among patients with no
GVHD (white circles), grade I aGVHD (gray circles), and grade II
o IV aGVHD (black circles) at 1 month (n  8, 13, and 9,
espectively) and 3 months (n  9, 10, and 7, respectively) after
ransplantation. Each circle represents an individual patient.
edian values are indicated as described in the legend to Figure 1.C Recovery
DC Plasmacytoid DC
6 mo 1 mo 3 mo 6 mo
.86 .05* .85 .07
.84 .3 .2 .69
1 .26 .65 .67
.6 .34 .29 .89
.62 .7 .18 .69
.84 .37 .49 .69
ND .2 .14 .54
.76 ND ND ND
nts’ peripheral blood at the indicated time points after transplantation were
pretransplantation factors. The signiﬁcance of each difference, determined
; ND, not done.P  .05.
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DC Reconstitution in PBSC Transplantation
Bated, because PB from patients receiving prednisone
oses 1 mg/kg had even lower CD11c DC and
D123 DC numbers. It is interesting to note that
atients who were receiving lower doses of CS (ie,
0.1 mg/kg) had both CD11cDC and CD123DC
umbers comparable to those of the patients who
ere not receiving steroids. However, PB numbers of
ther cell types, such as monocytes (Figure 4) and T
nd B lymphocytes (not shown), did not seem to vary
epending on the CS dose. Therefore, these data
uggest that treatment with steroids at a dose equiva-
ent to 0.1 mg/kg prednisone may correlate with a
elective reduction in the number of both circulating
D11c DC and CD123 DC in HSCT patients.
To test whether the recovery of CD11c DC
nd CD123 DC was affected by steroids at all time
oints after transplantation, patients were divided
nto 2 groups according to whether they were re-
eiving 0.1 mg/kg CS at the time of each blood
raw. As shown in Figure 5, patients receiving CS

igure 3. Chronic GVHD correlates with reduced PB CD123
C numbers at 6 months after transplantation. PB numbers of
D123DC (top), CD11cDC (middle), and monocytes (bottom)
ere compared between patients with no cGVHD (white circles)
nd cGVHD (black circles) at 6 months (n 7 and 10, respectively)
nd 12 months (n  6 and 9, respectively) after transplantation.
ach circle represents an individual patient. Median values are
ndicated as described in the legend to Figure 1. *P  .05.ad signiﬁcantly lower PB CD123 DC counts than a
B&MTther patients at all time points analyzed. PB
D11c DC counts also showed a similar trend,
lthough the difference was signiﬁcant only at 6
onths after transplantation (P  .05). Moreover,
hereas in patients who were not receiving CS,
oth CD123 DC and CD11c DC median counts
ere within the range observed in healthy donors
hroughout the entire observation period, in pa-
ients who were receiving CS, low numbers of DC
ere observed even as late as 1 year after transplan-
ation (Figure 5). It is interesting to note that PB
ounts of other leukocytes, such as monocytes, B
ells, and CD4 and CD8 T cells, did not differ in
he 2 groups at any of the indicated time points,
ith the exception of NK cells, which were signif-
cantly reduced in patients who were receiving CS
t 1 month after transplantation (P  .02; Figure 5
igure 4. Dose-dependent correlation between steroid treatment
nd PB DC numbers after PBSC transplantation. Samples were
ivided according to whether the patient was receiving no steroids,
p to 0.1 mg/kg, up to 1 mg/kg, or 1 mg/kg steroids at the time
f blood draw, and then PB numbers of CD123 DC (top),
D11c DC (middle), and monocytes (bottom) were compared
mong groups. Numbers of samples were 40, 11, 28, and 6 in the
roups with no, 0.1, 1, and 1 mg/kg steroids, respectively.
ach circle represents an individual sample. Median values are
ndicated as described in the legend to Figure 1. *P .05; **P .01;
**P  .001.nd data not shown).
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1cute GVHD Is an Independent Factor That
mpairs DC Recovery
Because DC recovery was apparently affected by
ge, aGVHD, and steroid treatment, we analyzed
hese factors in univariate and multivariate analysis.
amples obtained from patients at 1 and 3 months
fter transplantation were scored depending on the
ose of CS that the patient was receiving, the presence
f signs of active GVHD at the time of the blood
raw, and age. At 1 month after transplantation, in
nivariate analysis, both aGVHD (P  .0004) and
teroids (P  .03) affected the CD123 DC reconsti-
ution negatively (Table 3). Therefore, these 2 factors
ere analyzed in a multivariate analysis that showed
nly aGVHD to be an independent cause of reduced
D123 DC after allo-PBSC transplantation (P 

igure 5. Treatment with steroids after transplantation correlates
ith reduced PB CD123 DC and CD11c DC numbers. PB
umbers of DC2 (top), DC1 (middle), and monocytes (bottom)
ere compared between patients who were being treated (white
ircles) or not (black circles) with steroids at the indicated time
oints. The numbers of patients who were receiving steroids, as
ompared with the others, were, respectively: 17 and 11 at 1 month;
0 and 13 at 3 months; 4 and 15 at 6 months; and 3 and 12 at 12
onths. Circles represent median values. *P  .05; **P  .01.002; Table 3). CD11c DC reconstitution did not *
12orrelate signiﬁcantly with any of the factors tested
Table 3).
S, but Not cGVHD, Affect Late DC
econstitution
It is interesting to note that among patients at risk
or cGVHD, at 6 to 12 months after transplantation,
nly those receiving CS had signiﬁcantly reduced PB
D123 DC and CD11c DC median counts (P 
003 and P  .015, respectively). Chronic GVHD did
ot correlate with CD123 DC (P  .693) or with
D11c DC (P  .930) PB counts. Therefore, these
ata show that although aGVHD independently cor-
elates with reduced CD123 DC counts early (1
onth) after transplantation, at later time points (3-12
onths) CD123 DC and CD11c DC counts are
educed only in patients receiving steroids.
ISCUSSION
In this study we have analyzed the kinetics of
econstitution of 2 distinct DC subpopulations
CD11c DC and CD123 DC) in the PB of 31
atients receiving a fully myeloablative preparatory
egimen followed by allogeneic PBSC transplantation
rom HLA-identical sibling donors. Reconstitution of
oth CD11c DC and CD123 DC PB counts to
ormal levels takes 6 months to 1 year and is slower
han that of monocytes. Moreover, factors that poten-
ially affect DC reconstitution were identiﬁed, includ-
ng the development of aGVHD after transplantation
nd the treatment with CS.
It is now well established that human circulating
C are composed of at least 2 subsets, CD11c DC
nd CD123 DC, which possibly belong to distinct
ematopoietic lineages, ie, myeloid and lymphoid, re-
pectively [2-8]. Because CD11c DC and CD123
C may have different, even opposing, functions in
he regulation of immunity, we have used a ﬂow cy-
ometry–based method that could identify each subset
eparately from the other. Although there is no gen-
ral consensus yet as to the standard way to enumerate
able 3. Multivariate Analysis of the Signiﬁcance of the Correlation
etween Glucocorticoid Dose, Acute GVHD, and Age and the Number
f Circulating DC in Patients at 1 Month after Transplantation
Independent
Variable
Univariate
Analysis
Multivariate
Analysis
pDC mDC pDC mDC
ortisone dose .03* .40 .29 NA
cute GVHD .0004* .16 .004* NA
ge .47 .12 NA NA
A indicates not applicable; pDC, plasmacytoid DC; mDC, my-
eloid DC.Signiﬁcant.
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DC Reconstitution in PBSC Transplantation
BD11cDC and CD123DC in PB, our method has
een previously validated in clinical HSCT studies by
s and others [11,25,32]. Recently, new CD11cDC–
nd CD123 DC–related antigens have been charac-
erized (blood dendritic cell antigen [BDCA]-1
hrough -4) that may allow a more direct and simpler
ay to identify both subsets [33], and anti–BDCA-2
ntibodies may be effectively used for the enumera-
ion of CD123 DC in allogeneic HSCT patients
26,33].
Our data show that CD123 DC and CD11c
C counts are variably reduced early after transplan-
ation but, more importantly, that their reconstitution
ay be independently impaired by the development of
GVHD and the administration of CS. It is interest-
ng to note that the recovery of both DC subsets after
utologous transplantation of PBSC, either unma-
ipulated or CD34 selected, has been recently
hown to be faster than after allogeneic transplanta-
ion; most patients show normal levels of both
D11c DC and CD123 DC as early as 1 month
fter transplantation [34,35]. Therefore, it is con-
eivable that an early reconstitution of DC in the
utologous transplant setting may be favored by the
bsence of GVHD or treatment with immuno-
uppression.
Rabbit ATG has been shown to persist in the
irculation for some time after transplantation and
ay bind to DC-related antigens, such as CD86 [36].
or this reason, it is rather surprising that in this study
TG did not affect CD11c DC and CD123 DC
econstitution. Similarly, it has been recently observed
hat, although alemtuzumab (Campath-1G; Berlex
aboratories, Richmond, CA) may directly target PB
C in vivo, patients treated with alemtuzumab in
heir preparatory regimen did not show any impair-
ent in DC recovery [25,37]. However, more re-
ently, Morse et al. [38] have shown that alemtuzumab
ay selectively impair CD123, as opposed to
D11c, recovery. Moreover, DC recovery may be
aster after reduced-intensity as compared with my-
loablative preparatory regimens [27]. Also, graft
D11c DC and CD123 DC, as well as graft
D34, cell doses did not correlate with DC recon-
titution after transplantation [31]. It is interesting to
ote that in our series, neither TBI nor ATG corre-
ated with the development of GVHD. However,
hese data should be interpreted with caution because
f the low number of patients, which could limit the
tatistical power of the study.
Patients with aGVHD grade II to IV had fewer
irculating CD11c DC and CD123 DC, and the
reatment with CS further reduced DC numbers, par-
icularly CD123 DC, in the blood. However, blood
evels of all the other cell types tested were unaffected
y the development of aGVHD, with the exception of
cells, which seemed to be reduced in patients with t
B&MTevere aGVHD, as previously reported [28]. Although
t is not clear whether the development of GVHD is
ollowed by a decline in blood DC numbers or vice
ersa, because most patients had already developed
GVHD at the time of the ﬁrst blood draw (ie, 1
onth after transplantation), in the 2 patients who
eveloped aGVHD 30 days after transplantation,
D11c DC and CD123 DC levels strongly de-
reased after GVHD onset, suggesting that GVHD
ay indeed deplete circulating DC. Moreover, at
resent it is not clear why aGVHD may affect more
D123 DC than CD11c DC levels. One possible
ypothesis is that monocytic DC precursors, whose
umbers are unaffected, may at least partially replen-
sh the circulating CD11c DC pool. Reduced num-
ers of circulating DC in patients with aGVHD have
een previously reported also by Fearnley et al. [23],
lthough they did not distinguish between CD11c
C and CD123DC. Nevertheless, our ﬁndings may
lso raise the question of whether early recovery of
onor DC might prevent aGVHD. The observation
hat CS can reduce PB CD123 DC levels is in ac-
ordance with studies performed in clinical settings
ther than allogeneic HSCT, as well as in healthy
onors [39]. However, although CS have been shown
o affect the survival and function of CD11c DC in
itro [40], their effect on CD123 DC has not yet
een investigated.
In our study, cGVHD did not correlate with PB
C numbers. This is in contrast with a recent report
y Clark et al. [26], which showed that cGVHD may
e associated with increased numbers of circulating
D123 DC. This might be explained by differences
n methods of CD123 DC identiﬁcation or in drugs
dministered to the patients, eg, CS, that could pos-
ibly mask the increase in CD123 DC levels. More-
ver, a recent report has suggested that the develop-
ent of cGVHD may correlate with the presence of
easurable mixed chimerism within the pool of cir-
ulating APC, particularly monocytic DC precursors
41]. However, in most studies PB CD11c DC and
D123 DC have been shown to be consistently
00% of donor origin as early as 1 month after trans-
lantation [24-26]. Further studies are needed to eval-
ate chimerism levels in circulating and tissue-resi-
ent DC subsets late after allogeneic transplantation
n patients with or without GVHD.
In conclusion, our data suggest that the full recon-
titution of blood CD11c DC and CD123 DC
evels may be signiﬁcantly delayed after allogeneic
SCT because of aGVHD and its treatment with CS.
ifferent experimental evidence, as well as some clin-
cal studies in nontransplant settings, such as acquired
mmune deﬁciency syndrome [42], suggest that a lack
f DC may enhance the risk of opportunistic infec-
ions. Therefore, future studies will address whether
his is also the case in human HSCT. More impor-
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1antly, because aGVHD is likely to be triggered by
esidual host DC interacting with donor T lympho-
ytes, it could be hypothesized that administering CS
o HSCT patients shortly before starting the condi-
ioning regimen might selectively eliminate tissue DC
nd thus reduce the risk of aGVHD. In addition,
linical trials are warranted to address whether deple-
ion of CD11c DC, CD123 DC, or both in the
raft affects the incidence of GVHD and the dendritic
nd lymphoid immune reconstitution.
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